Achilles Therapeutics Ltd.

https://www.achillestx.com

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase 1/2a trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC). Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens. Achilles was founded in 2016 by lead investor Syncona Ltd and is supported by an international syndicate of life science investors including RA Capital, Forbion, Invus, Perceptive Advisors, Redmile Group, OrbiMed and Boxer Capital of Tavistock Group. *

	Start	2016-10-03 renamed
	Group	Achilles Therapeutics (Group)
	Predecessor	Achilles TX Ltd.
	Industry	T cell therapy
	Industry 2	cancer drug
	Person	Ali, Iraj (Achilles Therapeutics 201812– CEO before Interim CEO + Syncona + McKinsey)

	Region	Stevenage, Hertfordshire
	Country	United Kingdom (GB)
	Street	215 Gunnels Wood Road Stevenage Bioscience Catalyst
	City	SG1 2FX Stevenage, Hertfordshire
	Tel	+44-1438-906855
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Achilles Therapeutics Ltd.. (11/19/20). "Press Release: Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours". Stevenage.

		Record changed: 2025-03-16